Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT07284979 on ClinicalTrials.gov · last registry update 2026-09-01
An unusually large phase 3: 1,200 participants, more than double the 424 typical for the stage. Due to report March 2028, alongside 22 other tracked readouts that quarter. Primary outcome, as filed: Percent Change From Baseline in Body Weight at Week 76. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.
- Status
- RECRUITING
- Phase
- P3
- Drug
- semaglutideRybelsus, Wegovy, Ozempic
- Sponsor
- Kailera
- Sponsor type
- Industry
- Enrollment
- 1,200
- Started
- 2025-12-30
- Primary completion
- 2028-03 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent Change From Baseline in Body Weight at Week 76
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.